No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis

Prednisone is used as first-line therapy for pulmonary sarcoidosis. What dosing strategy has the best balance between effect and side-effects is largely unknown. We analyzed change in forced vital capacity (FVC) and weight during different prednisone doses used in daily practice for treatment na ïve pulmonary sarcoidosis patients.

Source: Respiratory Medicine - October 31, 2017 Category: Respiratory Medicine Authors: Caroline E. Broos, Linda H.C. Poell, Caspar W.N. Looman, Johannes C.C.M. In ’t Veen, Marco J.J.H. Grootenboers, Roxane Heller, Leon M. van den Toorn, Monique Wapenaar, Henk C. Hoogsteden, Mirjam Kool, Marlies S. Wijsenbeek, Bernt van den Blink Tags: Clinical Trial Paper Source Type: research